IL32 and non-small cell lung carcinoma: In fact, we identified interleukins such IL-6, IL-7 and IL-32 in our TS signatures, which have been previously linked with poor prognosis and metastasis in NSCLC.39–41 Hence, a follow-up study is needed to validate this correlation, as the two drugs are frequently combined.